tenofovir (Viread)

Advice

Following a full submission

tenofovir (Viread®) is accepted for use within NHS Scotland for the treatment of chronic hepatitis B in adults with compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.

Tenofovir has been shown to be significantly more effective than another nucleoside reverse transcriptase inhibitor in achieving a complete composite response (virological plus histological response) in a greater proportion of patients with chronic hepatitis B infection with HBeAg positive and HBeAg negative disease.